Abstract Details

Title Cervical dystonia patient’s satisfaction level after 3 years of botulinum toxin treatment

Topic Movement Disorders

Presentation(s) P4 - Poster Session 4 (5:30 PM-6:30 PM)

Poster/Presentation
Number 10-009

Objective Cervical dystonia (CD) typically requires regular repeat injections of botulinum toxin to maintain continued treatment efficacy. We aimed to track disease severity (as assessed by Toronto Western Spasmodic Torticollis Rating Scale [TWSTRS] scores) and subject satisfaction with abobotulinumtoxinA (AboBoNT-A) over 3 years of treatment.

Background Patient satisfaction is known to correlate with willingness to continue treatment.

Design/Methods INTEREST IN CD2 (NCT01753349) is an observational study following people with CD treated with BoNT-A over 3 years. At each injection visit, subject’s clinical status was assessed using TWSTRS and subjects reported satisfaction with the previous BoNT-A treatment cycle in 2 ways: (1) ‘Highest satisfaction’, assessing the highest level of satisfaction with symptom control over the previous cycle. (2) ‘Today satisfaction’, assessing current satisfaction at the end of treatment cycle.

Results 466 subjects were treated with AboBoNT-A over 3 years (median dose/number of treatment cycles: 500 units/10; 60.5% of subjects were reinjected with an interval of 12-16 weeks and 38.8% with a >16 weeks interval). Of these, 62% were female; mean age was 54.1 ±12.9 years and median time since diagnosis was 6.5 years. Over the course of 3 years treatment, subject levels of satisfaction (both types) remained relatively stable from the first to the last injection visit. Ratings of Highest satisfaction by time periods (84.1% - 91.2%) were higher than ratings of Today satisfaction (48.7% - 53.2%). This consistent level of satisfaction was in contrast to mean TWSTRS Total scores, which continued to decrease over the course of 3 years (from 33.0 at baseline to 25.6 at 3 years).

Conclusions In this study, despite continued improvements in clinical features (TWSTRS) over 3 years, subject satisfaction with symptom control remained relatively constant. This may indicate that factors other than symptom control also play a role in patient satisfaction.

Authors/Disclosures
Vivay Peter Misra, MD PRESENTER	No disclosure on file
	No disclosure on file
	No disclosure on file
Carlo Colosimo, MD (Universita La Sapienza)	No disclosure on file
Savary Om	No disclosure on file
Pascal Maisonobe	Pascal Maisonobe has received personal compensation for serving as an employee of ipsen pharma. Pascal Maisonobe has received personal compensation for serving as an employee of Ipsen.

��ɫ��

��ɫ��